Shattuck Labs Inc
NASDAQ:STTK

Watchlist Manager
Shattuck Labs Inc Logo
Shattuck Labs Inc
NASDAQ:STTK
Watchlist
Price: 3.15 USD 6.42% Market Closed
Market Cap: 199.3m USD

Shattuck Labs Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shattuck Labs Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Shattuck Labs Inc
NASDAQ:STTK
Net Issuance of Common Stock
$1.2m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.2B
CAGR 3-Years
3%
CAGR 5-Years
-16%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$2.2B
CAGR 3-Years
-123%
CAGR 5-Years
-191%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$3.5B
CAGR 3-Years
-62%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Shattuck Labs Inc
Glance View

Market Cap
198.9m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
0.27 USD
Overvaluation 91%
Intrinsic Value
Price

See Also

What is Shattuck Labs Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
1.2m USD

Based on the financial report for Dec 31, 2024, Shattuck Labs Inc's Net Issuance of Common Stock amounts to 1.2m USD.

What is Shattuck Labs Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
-14%

Over the last year, the Net Issuance of Common Stock growth was -97%. The average annual Net Issuance of Common Stock growth rates for Shattuck Labs Inc have been -14% over the past three years .

Back to Top